Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• MaXYuHGlobal burden of cancerYale J Biol Med2006793–4594
   Google Scholar
• HuangBZhaoJUnkelessJCFengZHXiongHTLR signaling by tumor and immune cells: a double-edged swordOncogene200827221822418176603
   PubMed Web of Science ®Google Scholar
• GorriniCHarrisISMakTWModulation of oxidative stress as an anticancer strategyNat Rev Drug Discov2013121293194724287781
   PubMed Web of Science ®Google Scholar
• MaQTranscriptional responses to oxidative stress: Pathological and toxicological implicationsPharmacol Ther2010125337639319945483
   PubMed Web of Science ®Google Scholar
• ValkoMRhodesCJMoncolJFree radicals, metals and antioxidants in oxidative stress-induced cancerChem Biol Interact2006160114016430879
   PubMed Web of Science ®Google Scholar
• StępkowskiTMKruszewskiMKMolecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosisFree Radic Biol Med20115091186119521295136
   PubMed Web of Science ®Google Scholar
• FuseYKobayashiMConservation of the Keap1-Nrf2 System: An evolutionary journey through stressful space and timeMolecules2017223436
   PubMed Web of Science ®Google Scholar
• MoiPChanKAsunisICaoAKanYWIsolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control regionProc Natl Acad Sci U S A19949121992699307937919
   PubMed Web of Science ®Google Scholar
• KansanenEKuosmanenSMLeinonenHLevonenA-LThe Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancerRedox Biol201311454924024136
   PubMed Web of Science ®Google Scholar
• TaguchiKMotohashiHYamamotoMMolecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolutionGenes Cells201116212314021251164
   PubMed Web of Science ®Google Scholar
• MoiPChanKAsunisICaoAKanYWIsolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control regionProc Natl Acad Sci U S A19949121992699307937919
   PubMed Web of Science ®Google Scholar
• ItohKWakabayashiNKatohYKeap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domainGenes Dev199913176869887101
   PubMed Web of Science ®Google Scholar
• ItohKMimuraJYamamotoMDiscovery of the Negative Regulator of Nrf2, Keap1: A Historical OverviewAntioxid Redox Signal201013111665167820446768
   PubMed Web of Science ®Google Scholar
• ItohKTongKIYamamotoMMolecular mechanism activating nrf2–keap1 pathway in regulation of adaptive response to electrophilesFree Radic Biol Med200436101208121315110385
   PubMed Web of Science ®Google Scholar
• PandeyPSinghAKSinghMThe see-saw of Keap1-Nrf2 pathway in cancerCrit Rev Oncol Hematol2017116899828693803
   PubMed Web of Science ®Google Scholar
• TongKIKatohYKusunokiHKeap1 recruits Neh2 through binding to ETGE and DLG motifs: Characterization of the two-site molecular recognition modelMol Cell Biol20062682887290016581765
   PubMed Web of Science ®Google Scholar
• LoSCLiXHenzlMTBeamerLJHanninkMStructure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signalingEmbo J200625153605361716888629
   PubMed Web of Science ®Google Scholar
• HörerSReinertDOstmannKHoevelsYNarHCrystal-contact engineering to obtain a crystal form of the Kelch domain of human Keap1 suitable for ligand-soaking experimentsActa Crystallogr Sect F Struct Biol Cryst Commun2013696592596
   PubMedGoogle Scholar
• CanningPSorrellFJBullockANStructural basis of Keap1 interactions with Nrf2Free Radic Biol Med201588Pt B10110726057936
   PubMed Web of Science ®Google Scholar
• GaoBDoanAHybertsonBMThe clinical potential of influencing Nrf2 signaling in degenerative and immunological disordersClin Pharmacol20146193424520207
   PubMedGoogle Scholar
• LuMCJiJAJiangZYYouQDThe Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: An UpdateMed Res Rev201636592496327192495
   PubMed Web of Science ®Google Scholar
• MilkovicLZarkovicNSasoLControversy about pharmacological modulation of Nrf2 for cancer therapyRedox Biol20171272773228411557
   PubMed Web of Science ®Google Scholar
• Krajka-KuźniakVPaluszczakJBaer-DubowskaWThe Nrf2-ARE signaling pathway: An update on its regulation and possible role in cancer prevention and treatmentPharmacol Rep201769339340228267640
   PubMed Web of Science ®Google Scholar
• MaQRole of Nrf2 in oxidative stress and toxicityAnnu Rev Pharmacol Toxicol201353140142623294312
   PubMed Web of Science ®Google Scholar
• LauAVilleneuveNSunZDual roles of Nrf2 in cancerPharmacol Res2008585–626227018838122
   PubMed Web of Science ®Google Scholar
• MenegonSColumbanoAGiordanoSThe dual roles of NRF2 in cancerTrends Mol Med201622757859327263465
   PubMed Web of Science ®Google Scholar
• MageshSChenYHuLSmall molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agentsMed Res Rev201232468772622549716
   PubMed Web of Science ®Google Scholar
• SandersKMoranZShiZNatural products for cancer prevention: Clinical update 2016Semin Oncol Nurs201632321524027539278
   PubMed Web of Science ®Google Scholar
• KouXKirbergerMYangYChenNNatural products for cancer prevention associated with Nrf2–ARE pathwayFood Sci Hum Wellness2013212228
   Google Scholar
• ZhaoCRGaoZHQuXJNrf2–ARE signaling pathway and natural products for cancer chemopreventionCancer Epidemiol201034552353320638930
   PubMed Web of Science ®Google Scholar
• CatanzaroECalcabriniCTurriniENrf2: a potential therapeutic target for naturally occurring anticancer drugs?Expert Opin Ther Targets201721878179328675319
   PubMed Web of Science ®Google Scholar
• ZhangYGordonGBA strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathwayMol Cancer Ther20043788589315252150
   PubMed Web of Science ®Google Scholar
• TaguchiKYamamotoMThe KEAP1–NRF2 System in CancerFront Oncol201778528523248
   PubMed Web of Science ®Google Scholar
• PitotHCGoldsworthyTMoranSThe natural history of carcinogenesis: Implications of experimental carcinogenesis in the genesis of human cancerJ Supramol Struct Cell Biochem19811721331467033553
   PubMedGoogle Scholar
• KlaunigJEKamendulisLMThe role of oxidative stress in carcinogenesisAnnu Rev Pharmacol Toxicol20044423926714744246
   PubMed Web of Science ®Google Scholar
• ZiechDFrancoRPappaAPanayiotidisMIReactive Oxygen Species (ROS) – Induced genetic and epigenetic alterations in human carcinogenesisMutat Res Fundam Mol Mech Mutagen20117111–2167173
   PubMed Web of Science ®Google Scholar
• ViscontiRGriecoDNew insights on oxidative stress in cancerCurr Opin Drug Discov Devel2009122240245
   PubMedGoogle Scholar
• van der WijstMGPBrownRRotsMGNrf2, the master redox switch: The Achilles’ heel of ovarian cancer?Biochim Biophys Acta20141846249450925270772
   PubMed Web of Science ®Google Scholar
• NguyenTNioiPPickettCBThe Nrf2-antioxidant response element signaling pathway and its activation by oxidative stressJ Biol Chem200928420132911329519182219
   PubMed Web of Science ®Google Scholar
• PadmanabhanBTongKIOhtaTStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancerMol Cell200621568970016507366
   PubMed Web of Science ®Google Scholar
• OhtaTIijimaKMiyamotoMLoss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growthCancer Res20086851303130918316592
   PubMed Web of Science ®Google Scholar
• YooNJKimHRKimYRAnCHLeeSHSomatic mutations of the KEAP1 gene in common solid cancersHistopathology201260694395222348534
   PubMed Web of Science ®Google Scholar
• SinghAMisraVThimmulappaRKDysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancerPLoS Med2006310e42017020408
   PubMed Web of Science ®Google Scholar
• NioiPNguyenTA mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activityBiochem Biophys Res Commun2007362481682117822677
   PubMed Web of Science ®Google Scholar
• ZhangPSinghAYegnasubramanianSLoss of Keap1 function in prostate cancer cells causes chemo- and radio-resistance and promotes tumor growthMol Cancer Ther20109233620124447
   PubMed Web of Science ®Google Scholar
• ShibataTKokubuAGotohMGenetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancerGastroenterology200813541358136818692501
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPASpentzosDFountzilasEKeap1 mutations and Nrf2 pathway activation in epithelial ovarian cancerCancer Res201171155081508921676886
   PubMed Web of Science ®Google Scholar
• ShibataTOhtaTTongKICancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancyProc Natl Acad Sci U S A200810536135681357318757741
   PubMed Web of Science ®Google Scholar
• KimYROhJEKimMSOncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skinJ Pathol2010220444645119967722
   PubMed Web of Science ®Google Scholar
• ShibataTKokubuASaitoSNRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancerNeoplasia201113986487321969819
   PubMed Web of Science ®Google Scholar
• WangRAnJJiFHypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissuesBiochem Biophys Res Commun2008373115115418555005
   PubMed Web of Science ®Google Scholar
• HanadaNTakahataTZhouQMethylation of the KEAP1 gene promoter region in human colorectal cancerBMC Cancer20121216622325485
   PubMed Web of Science ®Google Scholar
• IchimuraYWaguriSSouYSPhosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective AutophagyMol Cell201351561863124011591
   PubMed Web of Science ®Google Scholar
• InamiYWaguriSSakamotoAPersistent activation of Nrf2 through p62 in hepatocellular carcinoma cellsJ Cell Biol2011193227528421482715
   PubMed Web of Science ®Google Scholar
• OoiAWongJ-CPetilloDAn antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinomaCancer Cell201120451152322014576
   PubMed Web of Science ®Google Scholar
• HeXMaQNRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-Like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activationMol Pharmacol20097661265127819786557
   PubMed Web of Science ®Google Scholar
• WilsonAJKernsJKCallahanJFMoodyCJKeap Calm, and Carry on CovalentlyJ Med Chem201356197463747623837912
   PubMed Web of Science ®Google Scholar
• AbedDAGoldsteinMAlbanyanHDiscovery of direct inhibitors of Keap1–Nrf2 protein–protein interaction as potential therapeutic and preventive agentsActa Pharm Sin B20155428529926579458
   PubMed Web of Science ®Google Scholar
• ChenYInoyamaDKongA-NTKinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonanceChem Biol Drug Des20117861014102121920027
   PubMed Web of Science ®Google Scholar
• InoyamaDChenYHuangXOptimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interactionJ Biomol Screen201217443544722156223
   PubMedGoogle Scholar
• ZhuangCMiaoZShengCUpdated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a reviewCurr Med Chem201421161861187024533814
   PubMed Web of Science ®Google Scholar
• HancockRBertrandHCTsujitaTPeptide inhibitors of the Keap1–Nrf2 protein–protein interactionFree Radic Biol Med201252244445122107959
   PubMed Web of Science ®Google Scholar
• HancockR1SchaapMPfisterHWellsGPeptide inhibitors of the Keap1-Nrf2 protein-protein interaction with improved binding and cellular activityOrg Biomol Chem201311213553355723615671
   PubMed Web of Science ®Google Scholar
• SteelRCowanJPayerneEAnti-inflammatory effect of a cell-penetrating peptide targeting the Nrf2/Keap1 interactionACS Med Chem Lett20123540741022582137
   PubMed Web of Science ®Google Scholar
• HuLMageshSChenLDiscovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interactionBioorg Med Chem Lett201323103039304323562243
   PubMed Web of Science ®Google Scholar
• MarcotteDZengWHusJ-CSmall molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanismBioorg Med Chem201321144011401923647822
   PubMed Web of Science ®Google Scholar
• SinghAVenkannagariSOhKHSmall molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumorsACS Chem Biol201611113214322527552339
   PubMed Web of Science ®Google Scholar
• BollongMJYunHSherwoodLA small molecule inhibits deregulated NRF2 transcriptional activity in cancerACS Chem Biol201510102193219826270491
   PubMed Web of Science ®Google Scholar
• SunH-PJiangZ-YZhangM-YNovel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screeningMed Chem Commun2014519398
   Web of Science ®Google Scholar
• ZhuangCNarayanapillaiSZhangWRapid Identification of Keap1–Nrf2 Small-Molecule Inhibitors through Structure-Based Virtual Screening and Hit-Based Substructure SearchJ Med Chem20145731121112624417449
   PubMed Web of Science ®Google Scholar
• SatohMSaburiHTanakaTMultiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulationFEBS Open Bio201551557570
   PubMed Web of Science ®Google Scholar
• BertrandHCSchaapMBairdLDesign, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1–Nrf2 protein–protein interactionJ Med Chem201558187186719426348784
   PubMed Web of Science ®Google Scholar
• DaviesTGWixtedWECoyleJEMonoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein–protein interaction with high cell potency identified by fragment-based discoveryJ Med Chem20165983991400627031670
   PubMed Web of Science ®Google Scholar
• ZhongMLynchAJehleSFragment-based drug discovery targeting KEAP1/Nrf2 bindingFaseb J2015291_Suppl Abstract 712.20
   PubMedGoogle Scholar
• FosgerauKHoffmannTPeptide therapeutics: current status and future directionsDrug Discov Today201520112212825450771
   PubMed Web of Science ®Google Scholar
• JnoffEAlbrechtCBarkerJJBinding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complexChemMedChem20149469970524504667
   PubMed Web of Science ®Google Scholar
• JiangZYLuMCXuLLDiscovery of potent Keap1–Nrf2 protein–protein interaction inhibitor based on molecular binding determinants analysisJ Med Chem20145762736274524512214
   PubMed Web of Science ®Google Scholar
• JiangZYXuLLLuMCStructure-activity and structure-property relationship and exploratory in vivo evaluation of the nano-molar Keap1–Nrf2 protein–protein interaction inhibitorJ Med Chem201558166410642126258437
   PubMed Web of Science ®Google Scholar
• LiXZhangDHanninkMBeamerLJCrystal structure of the Kelch domain of human Keap1Journal of Biological Chemistry200427952547505475815475350
   PubMed Web of Science ®Google Scholar
• JainADPottetiHRichardsonBGProbing the structural requirements of non-electrophilic naphthalene-based Nrf2 activatorsEur J Med Chem201510325226826363505
   PubMed Web of Science ®Google Scholar
• SaitoTIchimuraYTaguchiKp62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogrammingNat Commun201671203027345495
   PubMed Web of Science ®Google Scholar
• WinkelAFEngelCKMargerieDCharacterization of RA839, a noncovalent small molecule binder to Keap1 and selective activator of Nrf2 signalingJ Biol Chem201529047284462845526459563
   PubMed Web of Science ®Google Scholar
• WahleKWJBrownIRotondoDHeysSDPlant phenolics in the prevention and treatment of cancerAdv Exp Med Biol2010698365121520702
   PubMed Web of Science ®Google Scholar
• HuangMTFerraroTPhenolic compounds in food and cancer preventionHuangMTHoCTLeeCYPhenolic Compounds in Food and their Effects on Health II: Antioxidants and Cancer PreventionWashington, DCAmerican Chemical Society1992834
   Google Scholar
• HatcherHPlanalpRChoJCurcumin: From ancient medicine to current clinical trialsCell Mol Life Sci200865111631165218324353
   PubMed Web of Science ®Google Scholar
• WhitlockNCBaekSJThe anticancer effects of resveratrol: Modulation of transcription factorsNutr Cancer201264449350222482424
   PubMed Web of Science ®Google Scholar
• RaufAImranMButtMSResveratrol as an anti-cancer agent: A reviewCrit Rev Food Sci Nutr20185891428144728001084
   PubMed Web of Science ®Google Scholar
• KunnumakkaraABAnandPAggarwalBBCurcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteinsCancer Lett2008269219922518479807
   PubMed Web of Science ®Google Scholar
• ChenBZhangYWangYCurcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expressionJ Steroid Biochem Mol Biol2014143111824486718
   PubMed Web of Science ®Google Scholar
• AdiwidjajaJMclachlanAJBoddyAVCurcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsExpert Opin Drug Metab Toxicol201713995397228776444
   PubMed Web of Science ®Google Scholar
• Burgos-MorónECalderón-MontañoJMSalvadorJRoblesALópez-LázaroMThe dark side of curcuminInt J Cancer201012671771177519830693
   PubMed Web of Science ®Google Scholar
• National Toxicology ProgramNTP toxicology and carcinogenesis studies of turmeric oleoresin (CAS No. 8024-37-1) (Major component 79%–85% curcumin, CAS No. 458-37-7) in F344/N rats and B6C3F1 mice (Feed studies)Natl Toxicol Program Tech Rep Ser1993427127512616304
   PubMedGoogle Scholar
• SinghBShoulsonRChatterjeeAResveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathwaysCarcinogenesis20143581872188024894866
   PubMed Web of Science ®Google Scholar
• LiCXuXWangXJPanYImine resveratrol analogues: Molecular design, Nrf2 activation and SAR analysisPLoS One201497e10145525028928
   PubMed Web of Science ®Google Scholar
• ChenCYuROwuorEDActivation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and deathArch Pharm Res200023660561211156183
   PubMed Web of Science ®Google Scholar
• HoughtonCAFassettRGCoombesJSSulforaphane and other nutrigenomic Nrf2 activators: Can the clinician’s expectation be matched by the reality?Oxid Med Cell Longev201620161, supplement78571861726881038
   PubMed Web of Science ®Google Scholar
• HanlonNColdhamNGielbertAAbsolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in ratBr J Nutr2008990355956417868493
   PubMed Web of Science ®Google Scholar
• RiedlMASaxonADiaz-SanchezDOral sulforaphane increases Phase II antioxidant enzymes in the human upper airwayClin Immu-nol20091303244251
   PubMed Web of Science ®Google Scholar
• YeLDinkova-KostovaATWadeKLQuantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humansClin Chim Acta20023161–2435311750273
   PubMed Web of Science ®Google Scholar
• CornblattBSYeLDinkova-KostovaATPreclinical and clinical evaluation of sulforaphane for chemoprevention in the breastCarcinogenesis20072871485149017347138
   PubMed Web of Science ®Google Scholar
• Dinkova-KostovaATFaheyJWKostovRVKenslerTWKEAP1 and done? Targeting the NRF2 pathway with sulforaphaneTrends Food Sci Technol201769Pt B25726929242678
   PubMed Web of Science ®Google Scholar
• RussoMSpagnuoloCRussoGLNrf2 targeting by sulforaphane: A potential therapy for cancer treatmentCrit Rev Food Sci Nutr20185881391140528001083
   PubMed Web of Science ®Google Scholar
• SunHZhuJLinHGuKFengFRecent progress in the development of small molecule Nrf2 modulators: a patent review (2012–2016)Expert Opin Ther Pat201727776378528454500
   PubMed Web of Science ®Google Scholar
• WangYYYangYXZheHHeZXZhouSFBardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic propertiesDrug Des Devel Ther2014820752088
   PubMed Web of Science ®Google Scholar
• HongDSKurzrockRSupkoJGA phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomasClin Cancer Res201218123396340622634319
   PubMed Web of Science ®Google Scholar
• CreelanBCGabrilovichDIGrayJESafety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumorsOnco Targets Ther2017104239425028919776
   PubMed Web of Science ®Google Scholar
• PatelSPHodiFSGabrilovichD5O_PRA phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanomaAnn Oncol201728suppl_11mdx760
   Google Scholar
• BenarrochEENrf2, cellular redox regulation, and neurologic implicationsNeurology201788201942195028424271
   PubMed Web of Science ®Google Scholar
• TuZSWangQSunDDDaiFZhouBDesign, synthesis, and evaluation of curcumin derivatives as Nrf2 activators and cytoprotectors against oxidative deathEur J Med Chem2017134728528399452
   PubMed Web of Science ®Google Scholar
• VyasADandawatePPadhyeSAhmadASarkarFPerspectives on new synthetic curcumin analogs and their potential anticancer propertiesCurr Pharm Des201319112047206923116312
   PubMed Web of Science ®Google Scholar
• KachadourianRDayBJPugazhentiSA synthetic chalcone as a potent inducer of glutathione biosynthesisJ Med Chem20125531382138822239485
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• LinkerRAHaghikiaADimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyTher Adv Chronic Dis20167419820727433310
   PubMed Web of Science ®Google Scholar
• SaiduNENoéGCerlesODimethyl fumarate controls the NRF2/DJ-1 axis in cancer cells: Therapeutic applicationsMol Cancer Ther201716352953928069874
   PubMed Web of Science ®Google Scholar
• Bennett SaiduNEBretagneMMansuetALDimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cellsOncotarget20189109088909929507676
   PubMedGoogle Scholar
• LoeweRValeroTKremlingSDimethyl fumarate impairs melanoma growth and metastasisCancer Res20066624118881189617178886
   PubMed Web of Science ®Google Scholar
• XiMYJiaJMSunHP3-aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as potent Nrf2/ARE inducers in human cancer cells and AOM-DSS treated miceJ Med Chem201356207925793824053646
   PubMed Web of Science ®Google Scholar
• ChildersWEAbou-GharbiaMBiswalSThimmulappaRKinventorsCureveda, LLC, assigneeFunctionalized heteroaryl enones exhibiting Nrf2 activation and their method of useUnited States patent USWO2015187934A1Cureveda, Llc20151210
   Google Scholar
• YouQYangTSunYinventorsChina Pharmaceutical University, assigneePyridopyrazine compounds as Nrf2 activators and their preparation, pharmaceutical compositions and use in the treatment of inflammation and cancerChinese patentCN105566323A2016511
   Google Scholar
• HarderBTianWLa ClairJJBrusatol overcomes chemoresistance through inhibition of protein translationMol Carcinog20175651493150028019675
   PubMed Web of Science ®Google Scholar
• ZhuJWangHChenFAn overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapyFree Radic Biol Med20169954455627634172
   PubMed Web of Science ®Google Scholar
• RenDVilleneuveNFJiangTBrusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanismProc Natl Acad Sci U S A201110841433143821205897
   PubMed Web of Science ®Google Scholar
• JaramilloMCZhangDDThe emerging role of the Nrf2-Keap1 signaling pathway in cancerGenes Dev201327202179219124142871
   PubMed Web of Science ®Google Scholar
• VartanianSMaTPLeeJApplication of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesisMol Cell Proteomics20161541220123126711467
   PubMed Web of Science ®Google Scholar
• HarderBTianWLa ClairJJBrusatol overcomes chemoresistance through inhibition of protein translationMol Carcinog20175651493150028019675
   PubMed Web of Science ®Google Scholar
• HallIHLeeKHEigebalySAAntitumor agents. XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cellsJ Pharm Sci1979687883887458610
   PubMed Web of Science ®Google Scholar
• RenDVilleneuveNFJiangTBrusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanismProc Natl Acad Sci U S A201110841433143821205897
   PubMed Web of Science ®Google Scholar
• TangWXieJXuSNovel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studiesJ Med Chem201457187600761225179783
   PubMed Web of Science ®Google Scholar
• TangXWangHFanLLuteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugsFree Radic Biol Med201150111599160921402146
   PubMed Web of Science ®Google Scholar
• GaoAMKeZPWangJNApigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathwayCarcinogenesis20133481806181423563091
   PubMed Web of Science ®Google Scholar
• GaoAMKeZPShiFSunGCChenHChrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathwayChem Biol Interact2013206110010823994249
   PubMed Web of Science ®Google Scholar
• LiaoJCLeeKTYouBJRaf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migrationFood Nutr Res2015592988426699938
   PubMed Web of Science ®Google Scholar
• BroekgaardenMWeijerRvan GulikTMHamblinMRHegerMTumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategiesCancer Metastasis Rev201534464369026516076
   PubMed Web of Science ®Google Scholar
• ArltASebensSKrebsSInhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activityOncogene201332404825483523108405
   PubMed Web of Science ®Google Scholar
• TsuchidaKTsujitaTHayashiMHalofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulationFree Radic Biol Med201710323624728039084
   PubMed Web of Science ®Google Scholar
• PinesMSpectorIHalofuginone – the multifaceted moleculeMolecules201520157359425569515
   PubMed Web of Science ®Google Scholar
• BiswalSSSinghARastinejadFinventorsNational Institutes of Health (NIH), Johns Hopkins University, Sanford-Burnham Prebys Medical Discovery Institute, assigneeNrf2 small molecule inhibitors for cancer therapyUnited States patentUS20160046616A12016218
   Google Scholar
• LiuXZhuQZhangMIsoliquiritigenin ameliorates acute pancreatitis in mice via inhibition of oxidative stress and modulation of the Nrf2/HO-1 pathwayOxid Med Cell Longev20182018 Article 7161592
   Web of Science ®Google Scholar
• ChoiEJJungBJLeeSHA clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancerOncogene201736375285529528504720
   PubMed Web of Science ®Google Scholar
• DuongHQYiYWKangHJInhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabineInt J Oncol201444395996924366069
   PubMed Web of Science ®Google Scholar